TB-500

Thymosin Beta-4 (Tβ4) is the naturally occurring 43-amino acid peptide found in virtually every mammalian cell. TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) representing the actin-binding domain of the parent molecule. TB-500 retains the cell-migratory and angiogenic activity of the full-length molecule but is a different — and shorter — compound. Critically, the human clinical trial data (the 2025 cardiac RCT, the Phase II/III ophthalmic trials) used full-length Tβ4, not TB-500. These results cannot be directly applied to TB-500.

The two peptides have mechanistically complementary — not redundant — effects. BPC-157 primarily acts locally at the injury site, promoting angiogenesis via VEGFR2, inhibiting NF-kB inflammation, and activating fibroblasts through the FAK-paxillin pathway. TB-500 acts more systemically, driving cell migration via G-actin sequestration and VEGF upregulation — helping repair-capable cells travel to the injury site. The combination addresses both the local repair environment and the systemic cell-recruitment needed to populate it. This complementary mechanism is the theoretical basis for the stack, though the combination has not been tested in controlled human trials.

As of February 2026, TB-500 is classified as an FDA 503A Category 2 bulk drug substance. This means licensed compounding pharmacies in the United States cannot legally compound it for human use. It is not a Schedule I controlled substance — possession is not typically criminalised — but the legal route to a legitimately compounded, quality-controlled supply has been closed in the US under current regulations. This is a more restrictive status than BPC-157, which was reclassified back to Category 1 in July 2026.

The full-length Tβ4 has a good tolerability profile in human clinical trials. Whether that safety profile extends to the TB-500 fragment is mechanistically plausible but not confirmed — the shorter peptide has not been studied in controlled human safety trials. Preclinical animal studies have not identified major adverse effects. Human safety data for TB-500 specifically does not exist.

The cardiac animal model data does include TB-500 fragment studies alongside full-length Tβ4 research. The preclinical cardiac evidence is genuinely strong and specifically includes the fragment. The 2025 RCT that showed positive human outcomes used full-length Tβ4 — that is where the distinction matters. For the mechanistic understanding of what TB-500 might do in cardiac tissue, the animal data is relevant. For clinical outcomes in humans, the full-length compound is what has been tested.

The most commonly cited research peptide protocol uses a loading phase of 2.0–2.5 mg administered subcutaneously twice weekly for 4–6 weeks, followed by a maintenance phase of 2.0 mg once weekly or once every two weeks. These protocols are derived from preclinical dosing scaled to human body weight and from practitioner anecdote — not from published human dose-ranging studies. No controlled human data exists to validate or refine these parameters.